Astrazeneca Ab

Grigorios Nikitidis

Stephen Connolly

Martin Hemmerling

Nafizal Hossain

Lena Elisabeth Ripa

Igor Shamovsky

Anna Kristoffersson

Susanne Elisabeth Berglund

Johan Rune Michael Lundkvist

Peter Storm

Erik Ringberg

Magnus Munck Af Rosenschöld

Robert Rönn

Jean-Claude Arnould

Antonios Nikitidis

Karolina Lawitz

Thomas Hansson

Petra Johannesson

Lars Pettersson

Thomas Geoffrey Colerick Bird

Joakim Larsson

Christian Tyrchan

Peter Olof Sjö

Håkan Bladh

Peter Nilsson

John Peter Bailey

Carita Nordén

Mikael Varga

Wesley Ralph Schaal

Malena Bengtsson

Carl Jonas Lindh

Edward Jolyon Griffen

Hanna Birgitta Ellinor Andersson

Henrik Johansson

Thomas Geoffrey Colerick Astrazeneca Reims Bird

Edward Jolyon Astrazeneca R & D Alderley Griffen

Jean-Claude Astrazeneca Reims Arnould

John Peter Astrazeneca R & D Alderley Bailey

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Chemical compounds

The present invention provides a compound of a formula (I): 

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD). 

There is provided compounds of formula I, wherein E, E, E, E, L, Y, Y, Y, Rand z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene Csynthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.

Compounds and uses

The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R, Rand Rare as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

5-heteroaryl thiazoles and their use as PI3K inhibitors

The use of compounds of formula (I) wherein R, R, R, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed 

Use of and some novel imidazopyridines

Compounds of formula (I) are modulators of STAT6 signal pathway activity, and can be used in the treatment of atopic dermatitis, urticaria, allergic asthma, allergic rhinitis, a food allergy, allergic conjunctivitis, hayfever, bullous pemphigoid, industrial sensitization, chronic rejection of transplants or COPD

Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof

Growing community of inventors

Mölndal, Sweden

Grigorios Nikitidis